Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing

Only around 20% of eligible US patients currently receive CAR-T therapy. Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.

Authors

Publication Details

Journal
Cell and Gene Therapy Insights
Published
2026-10-08
DOI
https://doi.org/10.18609/cgti.2026.117
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing

no authors
Cell and Gene Therapy Insights
CAR-T cell therapy research
article

Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing

no authors
article en

Abstract

Only around 20% of eligible US patients currently receive CAR-T therapy. Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.

Cell and Gene Therapy InsightsVol. 12(8)
Openalex Percentile: Top 17%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing — no authors · Cell and Gene Therapy Insights (2026) | TGRS Research Map | TGRS